News

Burden of psychiatric comorbidity higher in MS patients


 

References

The burden of psychiatric comorbidity is greater in patients with multiple sclerosis (MS), compared with the general population, reported Dr. Ruth Ann Marrie and coauthors from the departments of psychiatry and medicine at the University of Manitoba, Winnipeg.

A study of 44,452 MS patients and 220,849 controls in four Canadian provinces from 1995 to 2005 found that the incidence of depression in the MS group was 0.98% (95% CI; 0.81%-1.15%), compared with 0.72% (95% CI; 0.67%-0.76%) in the control group. The prevalence of depression was 20.1% in MS patients (19.5%-20.6%), compared with 11.9% (11.8%-12.1%) in the matched population, the authors noted.

HUNG KUO CHUN/Thinkstock

Also, the incidence and prevalence of anxiety disorder in the MS population was 0.64% (0.54%-0.73%) and 8.7% (8.4%-9.1%), respectively, compared with 0.42% (0.39%-0.45%) and 5.1% (4.9%-5.2%) in controls .

For bipolar disorder, the MS group had an incidence of 0.33% (0.26%-0.39%), compared with 0.16% (0.14%-0.18%) in controls. Prevalence was 4.7% (4.4%-4.9%) in the MS group and 2.3% (2.2%-2.3%) in controls .

Lastly, in schizophrenia, MS patients had an incidence of 0.060% (0.031%-0.080%), compared with 0.018% (0.011%-0.024%) in controls. Prevalence was 1.28% (1.15%-1.41%), in the MS group and 1.03% (0.99%-1.08%) in controls, the investigators said.

The findings suggest a “nonspecific effect of MS on psychiatric comorbidity,” Dr. Marrie and colleagues said in the report.

“From a policy perspective, this implies the need for general psychiatric support rather than illness-specific strategies,” they concluded.

Read the study in Neurology.

mrajaraman@frontlinemedcom.com

Recommended Reading

Stacey Cofield, PhD, of NARCOMS
MDedge Neurology
Sodium Channel Blockade With Phenytoin Has a Neuroprotective Effect After Acute Optic Neuritis
MDedge Neurology
Daclizumab’s efficacy against MS tempered by adverse events
MDedge Neurology
Ocrelizumab posts first-ever positive outcome data for primary progressive MS
MDedge Neurology
Ocrelizumab decreases relapses, brain lesion development in relapsing-remitting MS
MDedge Neurology
Vitamin D Levels in Multiple Sclerosis
MDedge Neurology
Generic Glatiramer Acetate in RRMS
MDedge Neurology
Barry Singer, MD
MDedge Neurology
Anti-TNFs May Double the Risk 
of Demyelinating Diseases
MDedge Neurology
Noninvasive Stimulation May Reduce 
Fatigue and Improve Memory in MS
MDedge Neurology